Table 2. Best overall tumor response of investigator-evaluation.
| Outcome | All patients (n=34) | Efficacy-evaluable patients (n=31) |
|---|---|---|
| Median follow-up (range), months | 12.2 (2.3–18.1) | – |
| Best overall response, n (%) | ||
| CR | 0 (0.0) | 0 (0.0) |
| PR | 14 (41.2) | 14 (45.2) |
| SD | 8 (23.5) | 8 (25.8) |
| PD | 12 (35.3) | 9 (29.0) |
| ORR, % (95% CI) | 41.2 (23.7–58.6) | 45.2 (26.6–63.7) |
| DCR, % (95% CI) | 64.7 (47.8–81.6) | 71.0 (54.0–87.9) |
| CBR, % (95% CI) | 44.1 (26.5–61.7) | 48.4 (29.8–67.0) |
| DOR, months (95% CI) | 6.9 (4.4–9.4) | 6.9 (4.4–9.4) |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; CI, confidence interval; DCR, disease control rate; CBR, clinical benefit response rate; DOR, duration of response.